Journal
ALZHEIMERS & DEMENTIA
Volume 11, Issue 2, Pages 195-206Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2014.06.006
Keywords
Biomarkers; Alzheimer's disease; Mild cognitive impairment; Diagnosis
Categories
Ask authors/readers for more resources
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid position emission tomography [PET], cerebrospinal fluid [CSF] A beta 42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it always/frequently) followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as moderate. Seventy-nine percent of responders felt very/extremely comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available